Integrated Diagnostics Holdings (LSE:IDHC) 3-Year RORE % : -15.83% (As of Mar. 2026)


LSE:IDHC Integrated Diagnostics Holdings PLC LSE:IDHC
58 GF Score
Price $0.51
GF Value $0.59
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Integrated Diagnostics Holdings 3-Year RORE %?

Integrated Diagnostics Holdings LSE:IDHC 58 3-Year RORE % is -15.83 as of Mar. 2026. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.59 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Integrated Diagnostics Holdings ranks worse than 57.43% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Integrated Diagnostics Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 was -15.83%.

The industry rank for Integrated Diagnostics Holdings's 3-Year RORE % or its related term are showing as below:

LSE:IDHC's 3-Year RORE % is ranked worse than
57.43% of 202 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.79 vs LSE:IDHC: -15.83

Integrated Diagnostics Holdings  (LSE:IDHC) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Integrated Diagnostics Holdings 3-Year RORE % Related Terms


Integrated Diagnostics Holdings 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Integrated Diagnostics Holdings's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Diagnostics Holdings 3-Year RORE % Chart

Integrated Diagnostics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 49.33 -122.22 -130.77 1,000.00

Integrated Diagnostics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -166.67 -130.77 -207.41 1,000.00 -15.83

LSE:IDHC vs TMO, DHR, IDXX: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Diagnostics Holdings 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Integrated Diagnostics Holdings's 3-Year RORE % falls into.


LSE:IDHC
58GF Score
Integrated Diagnostics Holdings PLC LSE:IDHC
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integrated Diagnostics Holdings 3-Year RORE % Calculation

Integrated Diagnostics Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.016-0.035 )/( 0.12-0 )
=-0.019/0.12
=-15.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -15.83 mean?
Integrated Diagnostics Holdings (LSE:IDHC) has a 3-Year RORE % of -15.83 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Integrated Diagnostics Holdings and its competitors. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #116 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 57.4%.
Is Integrated Diagnostics Holdings' 3-Year RORE % too high?
Integrated Diagnostics Holdings' current 3-Year RORE % is -15.83. Based on the distribution chart, Integrated Diagnostics Holdings ranks #116 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #116 out of 202 companies for 3-Year RORE %. This places Integrated Diagnostics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Integrated Diagnostics Holdings and its competitors. Integrated Diagnostics Holdings's current 3-Year RORE % is -15.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.59, compared to a current price of $0.51 — trading 13.6% below its estimated fair value. The current 3-Year RORE % is -15.83. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current 3-Year RORE % is -15.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued. The current stock price of $0.51 is trading 13.6% below its estimated GF Value™ of $0.59. GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.

Key valuation signals for LSE:IDHC:

  • 3-Year RORE %: -15.83
  • GF Value™: $0.59 vs. price of $0.51 (13.6% below fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integrated Diagnostics Holdings Business Description

Address 12 Castle Street, St Helier, JEY, JE2 3RT
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score

Get the complete analysis for LSE:IDHC

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.51
Price
$0.59
GF Value